Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Matthew R. Henn, Chief Scientific Officer and Executive Vice President at Seres Therapeutics, Inc. (NASDAQ:MCRB), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On February 18, Henn sold 3,953 shares of Seres Therapeutics common stock, generating $3,203 at a weighted average price of approximately $0.8104 per share. The stock currently trades at $0.83, with InvestingPro analysis indicating the company is currently undervalued. The company’s market capitalization stands at $141 million, with notably volatile stock price movements.
The sale was conducted under a Rule 10b5-1 trading plan established to cover taxes associated with the vesting of restricted stock units. Prior to this sale, Henn acquired 10,626 shares of common stock through the vesting of restricted stock units on February 15. These transactions reflect Henn’s ongoing management of his equity holdings in the company. InvestingPro analysis reveals the company faces challenges with cash burn and weak gross profit margins. For comprehensive insights into Seres Therapeutics’ financial health and future prospects, access the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Seres Therapeutics has received a $50 million installment payment from Nestlé Health Science as part of transition obligations following the sale of its VOWST business. The company anticipates an additional $25 million installment from Nestlé in July 2025, with these funds expected to support operations into the first quarter of 2026. Additionally, the FDA has granted Breakthrough Therapy designation to Seres’ investigational drug, SER-155, aimed at reducing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants. This designation follows promising Phase 1b study results showing a significant reduction in bacterial bloodstream infections compared to placebo. In corporate governance developments, Seres has expanded its Board of Directors with the appointment of Dr. Hans-Juergen Woerle, who brings extensive experience from his roles at Nestlé Health Science and other biopharmaceutical companies. Dr. Woerle’s appointment follows a rights agreement with Société des Produits Nestlé S.A., which holds a significant stake in Seres. These recent developments highlight Seres Therapeutics’ ongoing efforts to advance its pipeline and strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.